Table 3.

The potential benefit of the combination of GLP-1RA/SGLT2 inhibitor therapy [88,89,90,91].

Action	GLP-1RA	SGLT2 Inhibitor	Combination Therapies
Appetite	↓	↑?	↓
Body weight	↓↓	↓	↓↓↓
Insulin secretion	↑	↓	↑?
Glucagon	↓	→	→?
Body pressure	↓	↓	↓↓
Bone mineral density	↑?	↓?	→?
Muscle volume	↑?	↓?	→?
Amputation risk	→	↑ or →?	→?
Heart failure	↓	↓	↓↓
Renoprotection	+	+	++
Hepatic fat quantity	↓	↓	↓↓
Hepatic fibrosis	↓	↓?	↓?

GLP-1RA: glucagon-like peptide-1 receptor agonist, SGLT2: sodium-glucose cotransporter. ↑: increase, ↓: decrease, →: no change, ?: uncertain, +: positive effect.